View Future GrowthGimv 과거 순이익 실적과거 기준 점검 2/6Gimv은 연평균 11.5%의 비율로 수입이 증가해 온 반면, Capital Markets 산업은 수입이 0.9% 감소했습니다. 매출은 연평균 3%의 비율로 증가했습니다. Gimv의 자기자본이익률은 11.4%이고 순이익률은 76.5%입니다.핵심 정보11.49%순이익 성장률6.16%주당순이익(EPS) 성장률Capital Markets 산업 성장률15.20%매출 성장률3.03%자기자본이익률11.39%순이익률76.49%다음 순이익 업데이트03 Sep 2026최근 과거 실적 업데이트Reported Earnings • Feb 20Third quarter 2026 earnings released: EPS: €1.26 (vs €1.22 in 3Q 2025)Third quarter 2026 results: EPS: €1.26 (up from €1.22 in 3Q 2025). Revenue: €70.8m (up 25% from 3Q 2025). Net income: €46.4m (up 25% from 3Q 2025). Profit margin: 66% (in line with 3Q 2025). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.공고 • Jan 06Gimv NV to Report First Half, 2026 Results on Sep 03, 2026Gimv NV announced that they will report first half, 2026 results on Sep 03, 2026Reported Earnings • Nov 24First half 2026 earnings released: EPS: €3.40 (vs €5.15 in 1H 2025)First half 2026 results: EPS: €3.40 (down from €5.15 in 1H 2025). Revenue: €157.1m (down 16% from 1H 2025). Net income: €126.9m (down 12% from 1H 2025). Profit margin: 81% (up from 77% in 1H 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.공고 • Nov 23Gimv NV to Report Fiscal Year 2025 Final Results on Mar 30, 2026Gimv NV announced that they will report fiscal year 2025 final results on Mar 30, 2026공고 • Nov 22Gimv NV to Report Nine Months, 2026 Results on Feb 19, 2026Gimv NV announced that they will report nine months, 2026 results on Feb 19, 2026공고 • Oct 30Gimv NV to Report First Half, 2026 Results on Nov 20, 2025Gimv NV announced that they will report first half, 2026 results on Nov 20, 2025모든 업데이트 보기Recent updates공고 • Jul 02Impact Healthcare SA acquired an unknown majority stake in Les Psy Réunis SA from Gimv NV (ENXTBR:GIMB).Impact Healthcare SA acquired an unknown majority stake in Les Psy Réunis SA from Gimv NV (ENXTBR:GIMB) on June 30, 2026. Elizabeth and Andrei Cicotti will rollover of their existing stake. Christoph Neeracher, Thomas Rohde, Susanne Schreiber and Martin Leu of Bär & Karrer Ltd. acted as legal advisors for Gimv NV. Stout advised Elizabeth and Andrei Cicotti. Impact Healthcare SA completed the acquisition of an unknown majority stake in Les Psy Réunis SA from Gimv NV (ENXTBR:GIMB) on June 30, 2026.Board Change • Jun 22Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 9 experienced directors. 2 highly experienced directors. 5 independent directors (6 non-independent directors). Chairman of the Board Filip R. Dierckx was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Upcoming Dividend • May 25Upcoming dividend of €1.37 per shareEligible shareholders must have bought the stock before 01 June 2026. Payment date: 03 June 2026. Payout ratio is a comfortable 41% but the company is not cash flow positive. Trailing yield: 3.9%. Lower than top quartile of German dividend payers (4.5%). Higher than average of industry peers (2.9%).Reported Earnings • Feb 20Third quarter 2026 earnings released: EPS: €1.26 (vs €1.22 in 3Q 2025)Third quarter 2026 results: EPS: €1.26 (up from €1.22 in 3Q 2025). Revenue: €70.8m (up 25% from 3Q 2025). Net income: €46.4m (up 25% from 3Q 2025). Profit margin: 66% (in line with 3Q 2025). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.공고 • Feb 20+ 1 more updateGimv NV, Annual General Meeting, May 27, 2026Gimv NV, Annual General Meeting, May 27, 2026.공고 • Jan 06Gimv NV to Report First Half, 2026 Results on Sep 03, 2026Gimv NV announced that they will report first half, 2026 results on Sep 03, 2026공고 • Dec 16Ipsen S.A. (ENXTPA:IPN) completed the acquisition of ImCheck Therapeutics SAS from Kurma Partners SA, Gimv NV (ENXTBR:GIMB) and others.Ipsen S.A. (ENXTPA:IPN) entered into a definitive share purchase agreement to acquire ImCheck Therapeutics SAS from Kurma Partners SA, Gimv NV (ENXTBR:GIMB) and others for €1.4 billion on October 22, 2025. Under the terms of the agreement, through a wholly owned affiliate of Ipsen SAS, shareholders of ImCheck Therapeutics will receive a €350 million payment on a cash-free and debt-free basis at closing of the transaction, and deferred payments contingent upon the achievement of specified regulatory approvals and sales-based milestones, for a total potential consideration up to €1 billion. As a result of this transaction, Gimv will receive an upfront cash payment that represents a realized money multiple of 2.6x on our total investment and a positive impact of approximately €0.4 per share compared to the unaudited NAV communicated in the trading update at the beginning of September. Should all regulatory and sales-based milestones be achieved, this could result in a potential total money multiple of 7.1x, subject to the successful completion of these milestones. The transaction is expected to close by the end of first quarter of 2026, subject to fulfilment of customary closing conditions including the expiration or termination of any required regulatory and governmental approvals under French and U.S. regulations. Marc Castagnède, Olivier Picquerey, Laëtitia Bénard, Charles Tuffreau, Luc Lamblin, Laurie-Anne Ancenys and Charles del Valle of Allen & Overy France acted as legal advisor for Ipsen S.A. Centerview Partners acted as financial advisor for ImCheck Therapeutics SAS. Graham Defries and Kenny Walker-Durrant of Goodwin Procter Llp acted as legal advisor for ImCheck Therapeutics SAS. Dentons Europe, Association d'Avocats à Responsabilité Professionnelle Individuelle acted as legal advisor for ImCheck Therapeutics SAS. Allen & Overy LLP acted as legal advisor for Ipsen S.A. Ipsen S.A. (ENXTPA:IPN) completed the acquisition of ImCheck Therapeutics SAS from Kurma Partners SA, Gimv NV (ENXTBR:GIMB) and others on December 15, 2025.공고 • Nov 28Gimv NV (ENXTBR:GIMB) signed an definitive agreement to acquire an unknown minority stake in Equine Care Group from Compagnie Nationale a Portefeuille SA.Gimv NV (ENXTBR:GIMB) signed an definitive agreement to acquire an unknown minority stake in Equine Care Group from Compagnie Nationale a Portefeuille SA on November 27, 2025. By joining CNP, Bencis, the founders, managers and the veterinarians, Gimv becomes part of a very strong shareholder base united behind one ambition: to accelerate ECG’s development into the world’s leading one-stop partner for high-quality equine medicine, and to reinforce ECG’s position as the global leader for veterinary innovation, welfare, and professional excellence.Reported Earnings • Nov 24First half 2026 earnings released: EPS: €3.40 (vs €5.15 in 1H 2025)First half 2026 results: EPS: €3.40 (down from €5.15 in 1H 2025). Revenue: €157.1m (down 16% from 1H 2025). Net income: €126.9m (down 12% from 1H 2025). Profit margin: 81% (up from 77% in 1H 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.공고 • Nov 23Gimv NV to Report Fiscal Year 2025 Final Results on Mar 30, 2026Gimv NV announced that they will report fiscal year 2025 final results on Mar 30, 2026공고 • Nov 22Gimv NV to Report Nine Months, 2026 Results on Feb 19, 2026Gimv NV announced that they will report nine months, 2026 results on Feb 19, 2026공고 • Oct 30Gimv NV to Report First Half, 2026 Results on Nov 20, 2025Gimv NV announced that they will report first half, 2026 results on Nov 20, 2025공고 • Oct 22Ipsen S.A. (ENXTPA:IPN) entered into a definitive share purchase agreement to acquire ImCheck Therapeutics SAS from Kurma Partners SA, Gimv NV (ENXTBR:GIMB) and others for €1.4 billion.Ipsen S.A. (ENXTPA:IPN) entered into a definitive share purchase agreement to acquire ImCheck Therapeutics SAS from Kurma Partners SA, Gimv NV (ENXTBR:GIMB) and others for €1.4 billion on October 22, 2025. Under the terms of the agreement, through a wholly owned affiliate of Ipsen SAS, shareholders of ImCheck Therapeutics will receive a €350 million payment on a cash-free and debt-free basis at closing of the transaction, and deferred payments contingent upon the achievement of specified regulatory approvals and sales-based milestones, for a total potential consideration up to €1 billion. As a result of this transaction, Gimv will receive an upfront cash payment that represents a realized money multiple of 2.6x on our total investment and a positive impact of approximately €0.4 per share compared to the unaudited NAV communicated in the trading update at the beginning of September. Should all regulatory and sales-based milestones be achieved, this could result in a potential total money multiple of 7.1x, subject to the successful completion of these milestones. The transaction is expected to close by the end of first quarter of 2026, subject to fulfilment of customary closing conditions including the expiration or termination of any required regulatory and governmental approvals under French and U.S. regulations. Allen & Overy France acted as legal advisor for Ipsen S.A. Centerview Partners acted as financial advisor for ImCheck Therapeutics SAS. Goodwin Procter Llp acted as legal advisor for ImCheck Therapeutics SAS. Dentons Europe, Association d'Avocats à Responsabilité Professionnelle Individuelle acted as legal advisor for ImCheck Therapeutics SAS.공고 • Aug 29Gimv NV (ENXTBR:GIMB) entered into an agreement to acquire an unknown majority stake in Novicare B.V. from Gilde Healthcare Partners BV.Gimv NV (ENXTBR:GIMB) entered into an agreement to acquire an unknown majority stake in Novicare B.V. from Gilde Healthcare Partners BV on August 28, 2025. Gimv aims to support Novicare in response to the growing demand for specialized care services. The transaction is subject to customary regulatory approvals including works council approval.공고 • Jul 28Gimv NV (ENXTBR:GIMB) and the management of Hemink Groep B.V. completed the acquisition of an unknown majority stake in Hemink Groep B.V. from management and Pontex Investment Partners.Gimv NV (ENXTBR:GIMB) and the management of Hemink Groep B.V. agreed to acquire an unknown majority stake in Hemink Groep B.V. from management and Pontex Investment Partners on July 22, 2025. A cash consideration will be paid by Gimv NV and the management. The management will retain a minority stake in the new structure. Hemink's current management team will co-invest, underlining their long-term commitment to the company's further growth. As part of the acquisition, Hemink will continue to operate under its own identity, with the same people, the same approach and the same ambition. The transaction is subject to customary conditions, including regulatory approvals and approval by the competition authorities. The transaction is expected to close in 2025. Oaklins’ team in the Netherlands acted as the exclusive debt advisor to Gimv. Anke van Holthe tot Echten, Freek Hilberdink, Klaas Wiersma, Louis Lutz and Gianluca Kreuze of Loyens & Loeff acted as legal advisor for Gimv NV. Oaklins N.V. acted as debt advisor to Gimv NV. Bas Stoetzer and Geert Damman of Oaklins’ team in the Netherlands acted as the exclusive debt advisor to Gimv. Gimv NV (ENXTBR:GIMB) and the management of Hemink Groep B.V. completed the acquisition of an unknown majority stake in Hemink Groep B.V. from management and Pontex Investment Partners in July, 2025.공고 • Jul 23Gimv NV (ENXTBR:GIMB) and the management of Hemink Groep B.V. agreed to acquire an unknown majority stake in Hemink Groep B.V. from its former management and Pontex Investment Partners.Gimv NV (ENXTBR:GIMB) and the management of Hemink Groep B.V. agreed to acquire an unknown majority stake in Hemink Groep B.V. from its former management and Pontex Investment Partners on July 22, 2025. A cash consideration will be paid by Gimv NV and the management. The management will retain a minority stake in the new structure. Hemink's current management team will co-invest, underlining their long-term commitment to the company's further growth. As part of the acquisition, Hemink will continue to operate under its own identity, with the same people, the same approach and the same ambition. The transaction is subject to customary conditions, including regulatory approvals and approval by the competition authorities. The transaction is expected to close in 2025. Anke van Holthe tot Echten, Freek Hilberdink, Klaas Wiersma, Louis Lutz and Gianluca Kreuze of Loyens & Loeff acted as legal advisor for Gimv NV.공고 • Jun 25Gimv NV and the management of Alpine Nederland B.V. acquired an unknown majority stake in Alpine Nederland B.V. from Vendis Capital, founders and management of Alpine Nederland B.V.Gimv NV and the management of Alpine Nederland B.V. agreed to acquire an unknown majority stake in Alpine Nederland B.V. from Vendis Capital, founders and management of Alpine Nederland B.V. on June 24, 2025. The management team reinvests part of its proceeds. A cash consideration will be paid by Gimv NV and the management. As part of consideration, an undisclosed value is paid towards common equity of Alpine Nederland B.V. The transaction remains subject to the works council advisory procedure. Floris Pierik of Jones Day (Netherlands) acted as legal advisor to Gimv NV.공고 • Jun 24Cobepa S.A. acquired an unknown majority stake in Itineris NV from Participatiemaatschappij Vlaanderen NV, Gimv Arkiv II a fund managed by Gimv NV (ENXTBR:GIMB), SmartFin Capital I a fund managed by SmartFin Capital NV and Federal Holding and Investment Company.Cobepa S.A. acquired an unknown majority stake in Itineris NV from Participatiemaatschappij Vlaanderen NV, Gimv Arkiv II a fund managed by Gimv NV (ENXTBR:GIMB), SmartFin Capital I a fund managed by SmartFin Capital NV and Federal Holding and Investment Company on June 23, 2025. The investment marks a strong vote of confidence in Itineris’ strategy to become the global category leader in advanced software solutions for the utilities sector. Daiwa Corporate Advisory Limited acted as financial advisor for Itineris NV. Allen Overy Shearman Sterling LLP acted as legal advisor for Itineris NV. Four & Five acted as legal advisor for Itineris NV. Cobepa S.A. completed the acquisition of an unknown majority stake in Itineris NV from Participatiemaatschappij Vlaanderen NV, Gimv Arkiv II a fund managed by Gimv NV (ENXTBR:GIMB), SmartFin Capital I a fund managed by SmartFin Capital NV and Federal Holding and Investment Company on June 23, 2025.공고 • May 28Bugaboo International B.V. acquired an unknown minority stake in Joolz from Gimv NV (ENXTBR:GIMB).Bugaboo International B.V. acquired an unknown minority stake in Joolz from Gimv NV (ENXTBR:GIMB) on May 27, 2025. Both Joolz and Bugaboo have agreed to join forces to accelerate their international growth in the fragmented worldwide stroller market. Bugaboo International B.V. completed the acquisition of an unknown minority stake in Joolz from Gimv NV (ENXTBR:GIMB) on May 27, 2025.공고 • Mar 31Gimv NV to Report Fiscal Year 2025 Results on May 22, 2025Gimv NV announced that they will report fiscal year 2025 results on May 22, 2025New Risk • Mar 13New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 28% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks Paying a dividend despite having no free cash flows. Shareholders have been diluted in the past year (28% increase in shares outstanding).공고 • Feb 21Gimv NV agreed to acquired as unknown majority stake in The Spice Factory from Gilde Equity Management and Davy De Muyer.Gimv NV agreed to acquired as unknown majority stake in The Spice Factory from Gilde Equity Management and Davy De Muyer on February 20, 2025. Jorgen De Pelsmaeker, Chief Executive Officer, and the management team will reinvest alongside Gimv as the company embarks on its next phase of growth. Supported by the Gimv, The Spice Factory is expected to strengthen its market position and broaden its international reach. The transaction is expected to close before the end of March 2025.공고 • Feb 04Gimv NV (ENXTBR:GIMB) acquired an unknown minority stake in Robojob NV.Gimv NV (ENXTBR:GIMB) acquired an unknown minority stake in Robojob NV on February 3, 2025. The aim of Gimv’s investment is to support RoboJob's international growth and enable the company to realise the full potential of the promising product offering. With this strong foundation complemented with the partnership that Gimv and the De Roovere family are now entering into, RoboJob is now in optimal shape to realise its growth ambitions. Gimv NV (ENXTBR:GIMB) completed the acquisition of an unknown minority stake in Robojob NV on February 3, 2025.공고 • Dec 19B+N Referencia Zrt. agreed to acquire an unknown majority stake in Köberl Group from Gimv NV (ENXTBR:GIMB).B+N Referencia Zrt. agreed to acquire an unknown majority stake in Köberl Group from Gimv NV (ENXTBR:GIMB) on December 17, 2024. The deal is expected to close in the first quarter of 2025. Torsten Denker, Philipp Noack, Constantin vom Bauer, Olja Schmitt and Dominik Detels of IMAP Belgium acted as financial advisors for Gimv NV.공고 • Dec 06Gimv NV, Eric Merilhou, Yann Dauce and the management of Tibbloc acquired an unknown majority stake in Tibbloc from Ciclad, SAS.Gimv NV, Eric Merilhou, Yann Dauce and the management of Tibbloc acquired an unknown majority stake in Tibbloc from Ciclad, SAS on December 4, 2024. A cash consideration will be paid by Gimv NV and the management. As part of consideration, an undisclosed value is paid towards common equity of Tibbloc. For the period ending December 31, 2023, Tibbloc reported total revenue of €40 million. Gimv NV, Eric Merilhou, Yann Dauce and the management of Tibbloc completed the acqusition of an unknown majority stake in Tibbloc from Ciclad, SAS on December 4, 2024.공고 • Dec 04Gimv NV (ENXTBR:GIMB) and Wolf D. Koch agreed to acquire an unknown majority stake in Lupine Lighting Systems GmbH from Wolf D. Koch.Gimv NV (ENXTBR:GIMB) and Wolf D. Koch agreed to acquire an unknown majority stake in Lupine Lighting Systems GmbH from Wolf D. Koch on December 2, 2024. Wolf D. Koch, founder and chief executive officer, reinvesting part of his proceeds to hold a minority stake in the company. Financial details of the transaction remain undisclosed, pending successful closure.공고 • Nov 22Fremman Limited agreed to acquire an unknown majority stake in rehaneo GmbH from Gimv NV (ENXTBR:GIMB).Fremman Limited agreed to acquire an unknown majority stake in rehaneo GmbH from Gimv NV (ENXTBR:GIMB) on November 20, 2024. The financing will be provided by Ares. Founder and chief executive officer Bruno Crone and co-founder and Chief operating officer Christoph Dühr remain significantly invested in the company and continue their management roles. The transaction is subject to approval by the German antitrust authorities and is expected to close in Q1 2025. Isabell Hitzer and Dr. Bernd Egbers of Astera Legal acted as legal advisor for Fremman Limited. Latham & Watkins acted as legal advisor to Ares.공고 • Oct 16The Martens Brewery of Bocholt acquired United Dutch Breweries B.V. from Gimv NV (ENXTBR:GIMB) and management.The Martens Brewery of Bocholt acquired United Dutch Breweries B.V. from Gimv NV (ENXTBR:GIMB) and management on October 16, 2024. The Martens Brewery of Bocholt completed the acquisition of United Dutch Breweries B.V. from Gimv NV (ENXTBR:GIMB) and management on October 16, 2024.공고 • Sep 06BiZZdesign BV agreed to acquire MEGA International S.A. from Gimv NV (ENXTBR:GIMB).BiZZdesign BV agreed to acquire MEGA International S.A. from Gimv NV (ENXTBR:GIMB) on September 4, 2024. The transaction is subject to approval by regulatory board / committee.Upcoming Dividend • Jun 24Upcoming dividend of €1.82 per shareEligible shareholders must have bought the stock before 01 July 2024. Payment date: 26 July 2024. Payout ratio is a comfortable 33% but the company is not cash flow positive. Trailing yield: 5.7%. Within top quartile of German dividend payers (4.7%). Higher than average of industry peers (2.8%).New Risk • Jun 10New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Paying a dividend despite having no free cash flows. Shareholders have been diluted in the past year (2.4% increase in shares outstanding).공고 • May 22WorxInvest NV completed the acquisition of 27.81% stake in Gimv NV (ENXTBR:GIMB) from Flemish Community.WorxInvest NV signed an agreement to acquire 27.81% stake in Gimv NV (ENXTBR:GIMB) from Flemish Community for approximately €370 million on November 30, 2023. The transaction is subject to customary regulatory approvals., Freshfields Bruckhaus Deringer LLP and Ernst & Young served as accountant to WorxInvest on the transaction. Rothschild & Co and Stibbe advised the Flemish Region on the transaction. Morgan Stanley acted as financial advisor to WorxInvest NV. Koen Vanhaerents, Guillaume Nataf, Frans Muller and Bram Hoorelbeke of Baker & Mckenzie acted as legal advisor to Gimv. As of April 15, 2024, The European Commission approved WorxInvest to buy Gimv.WorxInvest NV completed the acquisition of 27.81% stake in Gimv NV (ENXTBR:GIMB) from Flemish Community on May 21, 2024. All regulatory approvals obtained.Board Change • May 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Mar 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.공고 • Feb 28Sagard SAS acquired Groupe Acceo from Gimv NV (ENXTBR:GIMB).Sagard SAS acquired Groupe Acceo from Gimv NV (ENXTBR:GIMB) on February 27, 2024. Moncey Avocats acted as legal advisor, Natixis Partners and UBS M & A Mid-Cap acted as financial advisor, KPMG Corporate Finance France, Indefi and Marsh & Mclennan Companies France acted as due diligence provider to Sagard SAS. Capitalmind Corporate Finance Advisory acted as financial advisor, Hogan Lovells (Paris) LLP acted as legal advisor, Oderis Consulting and EY-Parthenon acted as due diligence provider to Groupe Acceo shareholders. Sagard SAS completed the acquisition of Groupe Acceo from Gimv NV (ENXTBR:GIMB) on February 27, 2024.Board Change • Feb 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.공고 • Feb 03+ 2 more updatesGimv NV to Report Fiscal Year 2024 Results on May 23, 2024Gimv NV announced that they will report fiscal year 2024 results on May 23, 2024Reported Earnings • Nov 25First half 2024 earnings released: EPS: €5.81 (vs €2.80 loss in 1H 2023)First half 2024 results: EPS: €5.81 (up from €2.80 loss in 1H 2023). Revenue: €203.5m (up 86% from 1H 2023). Net income: €158.2m (up €233.2m from 1H 2023). Profit margin: 78% (up from net loss in 1H 2023). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.Board Change • Nov 24Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Oct 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.공고 • Sep 19Crédit Mutuel Equity signed an agreement to acquire unknown majority stake in Groupe CLAIRE SAS from Gimv NV (ENXTBR:GIMB).Crédit Mutuel Equity signed an agreement to acquire unknown majority stake in Groupe CLAIRE SAS from Gimv NV (ENXTBR:GIMB) on September 18, 2023. Completion of the transaction remains subject to the recommendation of Groupe Claire's employee representative bodies, as well as the authorization of the French Competition Authority.Board Change • Apr 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Feb 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Jan 12First half 2023 earnings released: €2.80 loss per share (vs €5.22 profit in 1H 2022)First half 2023 results: €2.80 loss per share (down from €5.22 profit in 1H 2022). Revenue: €109.3m (down 48% from 1H 2022). Net loss: €75.1m (down 155% from profit in 1H 2022). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.Board Change • Jan 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Nov 17Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.공고 • Oct 26Gimv NV to Report Fiscal Year 2023 Results on May 17, 2023Gimv NV announced that they will report fiscal year 2023 results on May 17, 2023공고 • Oct 19Gimv NV, Annual General Meeting, Jun 28, 2023Gimv NV, Annual General Meeting, Jun 28, 2023.Board Change • Sep 12Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Jul 25Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Jan 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Dec 17Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Nov 21First half 2022 earnings released: EPS €5.22 (vs €3.61 in 1H 2021)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2022 results: Revenue: €208.5m (up 21% from 1H 2021). Net income: €137.0m (up 46% from 1H 2021). Profit margin: 66% (up from 55% in 1H 2021). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.Board Change • Nov 12Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Sep 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • May 22Full year 2021 earnings released: EPS €7.96 (vs €5.96 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: €331.9m (up 125% from FY 2020). Net income: €205.7m (up €357.3m from FY 2020). Profit margin: 62% (up from net loss in FY 2020). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Mar 05New 90-day low: €48.40The company is down 1.0% from its price of €49.10 on 04 December 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Capital Markets industry, which is up 10.0% over the same period.Is New 90 Day High Low • Feb 03New 90-day high: €50.80The company is up 12% from its price of €45.50 on 04 November 2020. The German market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Capital Markets industry, which is up 14% over the same period.Is New 90 Day High Low • Dec 28New 90-day high: €50.30The company is up 6.0% from its price of €47.40 on 29 September 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Capital Markets industry, which is also up 6.0% over the same period.Reported Earnings • Nov 22First half 2021 earnings released: EPS €3.61The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €172.5m (up 12% from 1H 2020). Net income: €94.0m (up 83% from 1H 2020). Profit margin: 55% (up from 33% in 1H 2020). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 81% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Nov 19New 90-day high: €48.10The company is up 6.0% from its price of €45.50 on 20 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Capital Markets industry, which is down 3.0% over the same period.Is New 90 Day High Low • Oct 22New 90-day low: €45.00The company is down 4.0% from its price of €46.85 on 24 July 2020. The German market is down 3.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Capital Markets industry, which is down 10.0% over the same period.매출 및 비용 세부 내역Gimv가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이BST:GI3 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비31 Dec 2530223150030 Sep 2527120149030 Jun 2528621050031 Mar 2530121956031 Dec 2428821146030 Sep 2427620436030 Jun 2428421034031 Mar 2429221732031 Dec 2327219528030 Sep 2325117423030 Jun 231255722031 Mar 23-2-5922031 Dec 22-5-4930030 Sep 22-7-3838030 Jun 221236837031 Mar 2225217437031 Dec 2131021128030 Sep 2136724920030 Jun 2134922719031 Mar 2133120618031 Dec 202484817030 Sep 20166-10916030 Jun 20156-13017031 Mar 20147-15218031 Dec 19208-2514030 Sep 1927010142030 Jun 1924810737031 Mar 1922611217031 Dec 1822211041030 Sep 1821910719030 Jun 1822610719031 Mar 1823410735031 Dec 1722110819030 Sep 1720910919030 Jun 1723812120031 Mar 1726613221031 Dec 1629814521030 Sep 1633015720030 Jun 1629714720031 Mar 1626413719031 Dec 1526614519030 Sep 15268152190양질의 수익: GI3의 비현금 수익 수준이 높습니다.이익 마진 증가: GI3의 현재 순 이익률 (76.5%)은 지난해 (73.3%)보다 높습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: GI3의 수익은 지난 5년 동안 연평균 11.5% 증가했습니다.성장 가속화: 지난 1년간 GI3 의 수익 증가율(9.3%)은 5년 평균(연간 11.5%)보다 낮습니다.수익 대 산업: GI3의 지난 1년 수익 증가율(9.3%)은 Capital Markets 업계 평균(39.6%)을 능가하지 못했습니다.자기자본이익률높은 ROE: GI3의 자본 수익률(11.4%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YDiversified-financials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/27 04:48종가2026/07/24 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Gimv NV는 6명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Olivier Van DoosselaereBNP ParibasAlexi GantelmeBNP ParibasKris KippersDegroof Petercam3명의 분석가 더 보기
Reported Earnings • Feb 20Third quarter 2026 earnings released: EPS: €1.26 (vs €1.22 in 3Q 2025)Third quarter 2026 results: EPS: €1.26 (up from €1.22 in 3Q 2025). Revenue: €70.8m (up 25% from 3Q 2025). Net income: €46.4m (up 25% from 3Q 2025). Profit margin: 66% (in line with 3Q 2025). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
공고 • Jan 06Gimv NV to Report First Half, 2026 Results on Sep 03, 2026Gimv NV announced that they will report first half, 2026 results on Sep 03, 2026
Reported Earnings • Nov 24First half 2026 earnings released: EPS: €3.40 (vs €5.15 in 1H 2025)First half 2026 results: EPS: €3.40 (down from €5.15 in 1H 2025). Revenue: €157.1m (down 16% from 1H 2025). Net income: €126.9m (down 12% from 1H 2025). Profit margin: 81% (up from 77% in 1H 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
공고 • Nov 23Gimv NV to Report Fiscal Year 2025 Final Results on Mar 30, 2026Gimv NV announced that they will report fiscal year 2025 final results on Mar 30, 2026
공고 • Nov 22Gimv NV to Report Nine Months, 2026 Results on Feb 19, 2026Gimv NV announced that they will report nine months, 2026 results on Feb 19, 2026
공고 • Oct 30Gimv NV to Report First Half, 2026 Results on Nov 20, 2025Gimv NV announced that they will report first half, 2026 results on Nov 20, 2025
공고 • Jul 02Impact Healthcare SA acquired an unknown majority stake in Les Psy Réunis SA from Gimv NV (ENXTBR:GIMB).Impact Healthcare SA acquired an unknown majority stake in Les Psy Réunis SA from Gimv NV (ENXTBR:GIMB) on June 30, 2026. Elizabeth and Andrei Cicotti will rollover of their existing stake. Christoph Neeracher, Thomas Rohde, Susanne Schreiber and Martin Leu of Bär & Karrer Ltd. acted as legal advisors for Gimv NV. Stout advised Elizabeth and Andrei Cicotti. Impact Healthcare SA completed the acquisition of an unknown majority stake in Les Psy Réunis SA from Gimv NV (ENXTBR:GIMB) on June 30, 2026.
Board Change • Jun 22Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 9 experienced directors. 2 highly experienced directors. 5 independent directors (6 non-independent directors). Chairman of the Board Filip R. Dierckx was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Upcoming Dividend • May 25Upcoming dividend of €1.37 per shareEligible shareholders must have bought the stock before 01 June 2026. Payment date: 03 June 2026. Payout ratio is a comfortable 41% but the company is not cash flow positive. Trailing yield: 3.9%. Lower than top quartile of German dividend payers (4.5%). Higher than average of industry peers (2.9%).
Reported Earnings • Feb 20Third quarter 2026 earnings released: EPS: €1.26 (vs €1.22 in 3Q 2025)Third quarter 2026 results: EPS: €1.26 (up from €1.22 in 3Q 2025). Revenue: €70.8m (up 25% from 3Q 2025). Net income: €46.4m (up 25% from 3Q 2025). Profit margin: 66% (in line with 3Q 2025). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
공고 • Feb 20+ 1 more updateGimv NV, Annual General Meeting, May 27, 2026Gimv NV, Annual General Meeting, May 27, 2026.
공고 • Jan 06Gimv NV to Report First Half, 2026 Results on Sep 03, 2026Gimv NV announced that they will report first half, 2026 results on Sep 03, 2026
공고 • Dec 16Ipsen S.A. (ENXTPA:IPN) completed the acquisition of ImCheck Therapeutics SAS from Kurma Partners SA, Gimv NV (ENXTBR:GIMB) and others.Ipsen S.A. (ENXTPA:IPN) entered into a definitive share purchase agreement to acquire ImCheck Therapeutics SAS from Kurma Partners SA, Gimv NV (ENXTBR:GIMB) and others for €1.4 billion on October 22, 2025. Under the terms of the agreement, through a wholly owned affiliate of Ipsen SAS, shareholders of ImCheck Therapeutics will receive a €350 million payment on a cash-free and debt-free basis at closing of the transaction, and deferred payments contingent upon the achievement of specified regulatory approvals and sales-based milestones, for a total potential consideration up to €1 billion. As a result of this transaction, Gimv will receive an upfront cash payment that represents a realized money multiple of 2.6x on our total investment and a positive impact of approximately €0.4 per share compared to the unaudited NAV communicated in the trading update at the beginning of September. Should all regulatory and sales-based milestones be achieved, this could result in a potential total money multiple of 7.1x, subject to the successful completion of these milestones. The transaction is expected to close by the end of first quarter of 2026, subject to fulfilment of customary closing conditions including the expiration or termination of any required regulatory and governmental approvals under French and U.S. regulations. Marc Castagnède, Olivier Picquerey, Laëtitia Bénard, Charles Tuffreau, Luc Lamblin, Laurie-Anne Ancenys and Charles del Valle of Allen & Overy France acted as legal advisor for Ipsen S.A. Centerview Partners acted as financial advisor for ImCheck Therapeutics SAS. Graham Defries and Kenny Walker-Durrant of Goodwin Procter Llp acted as legal advisor for ImCheck Therapeutics SAS. Dentons Europe, Association d'Avocats à Responsabilité Professionnelle Individuelle acted as legal advisor for ImCheck Therapeutics SAS. Allen & Overy LLP acted as legal advisor for Ipsen S.A. Ipsen S.A. (ENXTPA:IPN) completed the acquisition of ImCheck Therapeutics SAS from Kurma Partners SA, Gimv NV (ENXTBR:GIMB) and others on December 15, 2025.
공고 • Nov 28Gimv NV (ENXTBR:GIMB) signed an definitive agreement to acquire an unknown minority stake in Equine Care Group from Compagnie Nationale a Portefeuille SA.Gimv NV (ENXTBR:GIMB) signed an definitive agreement to acquire an unknown minority stake in Equine Care Group from Compagnie Nationale a Portefeuille SA on November 27, 2025. By joining CNP, Bencis, the founders, managers and the veterinarians, Gimv becomes part of a very strong shareholder base united behind one ambition: to accelerate ECG’s development into the world’s leading one-stop partner for high-quality equine medicine, and to reinforce ECG’s position as the global leader for veterinary innovation, welfare, and professional excellence.
Reported Earnings • Nov 24First half 2026 earnings released: EPS: €3.40 (vs €5.15 in 1H 2025)First half 2026 results: EPS: €3.40 (down from €5.15 in 1H 2025). Revenue: €157.1m (down 16% from 1H 2025). Net income: €126.9m (down 12% from 1H 2025). Profit margin: 81% (up from 77% in 1H 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
공고 • Nov 23Gimv NV to Report Fiscal Year 2025 Final Results on Mar 30, 2026Gimv NV announced that they will report fiscal year 2025 final results on Mar 30, 2026
공고 • Nov 22Gimv NV to Report Nine Months, 2026 Results on Feb 19, 2026Gimv NV announced that they will report nine months, 2026 results on Feb 19, 2026
공고 • Oct 30Gimv NV to Report First Half, 2026 Results on Nov 20, 2025Gimv NV announced that they will report first half, 2026 results on Nov 20, 2025
공고 • Oct 22Ipsen S.A. (ENXTPA:IPN) entered into a definitive share purchase agreement to acquire ImCheck Therapeutics SAS from Kurma Partners SA, Gimv NV (ENXTBR:GIMB) and others for €1.4 billion.Ipsen S.A. (ENXTPA:IPN) entered into a definitive share purchase agreement to acquire ImCheck Therapeutics SAS from Kurma Partners SA, Gimv NV (ENXTBR:GIMB) and others for €1.4 billion on October 22, 2025. Under the terms of the agreement, through a wholly owned affiliate of Ipsen SAS, shareholders of ImCheck Therapeutics will receive a €350 million payment on a cash-free and debt-free basis at closing of the transaction, and deferred payments contingent upon the achievement of specified regulatory approvals and sales-based milestones, for a total potential consideration up to €1 billion. As a result of this transaction, Gimv will receive an upfront cash payment that represents a realized money multiple of 2.6x on our total investment and a positive impact of approximately €0.4 per share compared to the unaudited NAV communicated in the trading update at the beginning of September. Should all regulatory and sales-based milestones be achieved, this could result in a potential total money multiple of 7.1x, subject to the successful completion of these milestones. The transaction is expected to close by the end of first quarter of 2026, subject to fulfilment of customary closing conditions including the expiration or termination of any required regulatory and governmental approvals under French and U.S. regulations. Allen & Overy France acted as legal advisor for Ipsen S.A. Centerview Partners acted as financial advisor for ImCheck Therapeutics SAS. Goodwin Procter Llp acted as legal advisor for ImCheck Therapeutics SAS. Dentons Europe, Association d'Avocats à Responsabilité Professionnelle Individuelle acted as legal advisor for ImCheck Therapeutics SAS.
공고 • Aug 29Gimv NV (ENXTBR:GIMB) entered into an agreement to acquire an unknown majority stake in Novicare B.V. from Gilde Healthcare Partners BV.Gimv NV (ENXTBR:GIMB) entered into an agreement to acquire an unknown majority stake in Novicare B.V. from Gilde Healthcare Partners BV on August 28, 2025. Gimv aims to support Novicare in response to the growing demand for specialized care services. The transaction is subject to customary regulatory approvals including works council approval.
공고 • Jul 28Gimv NV (ENXTBR:GIMB) and the management of Hemink Groep B.V. completed the acquisition of an unknown majority stake in Hemink Groep B.V. from management and Pontex Investment Partners.Gimv NV (ENXTBR:GIMB) and the management of Hemink Groep B.V. agreed to acquire an unknown majority stake in Hemink Groep B.V. from management and Pontex Investment Partners on July 22, 2025. A cash consideration will be paid by Gimv NV and the management. The management will retain a minority stake in the new structure. Hemink's current management team will co-invest, underlining their long-term commitment to the company's further growth. As part of the acquisition, Hemink will continue to operate under its own identity, with the same people, the same approach and the same ambition. The transaction is subject to customary conditions, including regulatory approvals and approval by the competition authorities. The transaction is expected to close in 2025. Oaklins’ team in the Netherlands acted as the exclusive debt advisor to Gimv. Anke van Holthe tot Echten, Freek Hilberdink, Klaas Wiersma, Louis Lutz and Gianluca Kreuze of Loyens & Loeff acted as legal advisor for Gimv NV. Oaklins N.V. acted as debt advisor to Gimv NV. Bas Stoetzer and Geert Damman of Oaklins’ team in the Netherlands acted as the exclusive debt advisor to Gimv. Gimv NV (ENXTBR:GIMB) and the management of Hemink Groep B.V. completed the acquisition of an unknown majority stake in Hemink Groep B.V. from management and Pontex Investment Partners in July, 2025.
공고 • Jul 23Gimv NV (ENXTBR:GIMB) and the management of Hemink Groep B.V. agreed to acquire an unknown majority stake in Hemink Groep B.V. from its former management and Pontex Investment Partners.Gimv NV (ENXTBR:GIMB) and the management of Hemink Groep B.V. agreed to acquire an unknown majority stake in Hemink Groep B.V. from its former management and Pontex Investment Partners on July 22, 2025. A cash consideration will be paid by Gimv NV and the management. The management will retain a minority stake in the new structure. Hemink's current management team will co-invest, underlining their long-term commitment to the company's further growth. As part of the acquisition, Hemink will continue to operate under its own identity, with the same people, the same approach and the same ambition. The transaction is subject to customary conditions, including regulatory approvals and approval by the competition authorities. The transaction is expected to close in 2025. Anke van Holthe tot Echten, Freek Hilberdink, Klaas Wiersma, Louis Lutz and Gianluca Kreuze of Loyens & Loeff acted as legal advisor for Gimv NV.
공고 • Jun 25Gimv NV and the management of Alpine Nederland B.V. acquired an unknown majority stake in Alpine Nederland B.V. from Vendis Capital, founders and management of Alpine Nederland B.V.Gimv NV and the management of Alpine Nederland B.V. agreed to acquire an unknown majority stake in Alpine Nederland B.V. from Vendis Capital, founders and management of Alpine Nederland B.V. on June 24, 2025. The management team reinvests part of its proceeds. A cash consideration will be paid by Gimv NV and the management. As part of consideration, an undisclosed value is paid towards common equity of Alpine Nederland B.V. The transaction remains subject to the works council advisory procedure. Floris Pierik of Jones Day (Netherlands) acted as legal advisor to Gimv NV.
공고 • Jun 24Cobepa S.A. acquired an unknown majority stake in Itineris NV from Participatiemaatschappij Vlaanderen NV, Gimv Arkiv II a fund managed by Gimv NV (ENXTBR:GIMB), SmartFin Capital I a fund managed by SmartFin Capital NV and Federal Holding and Investment Company.Cobepa S.A. acquired an unknown majority stake in Itineris NV from Participatiemaatschappij Vlaanderen NV, Gimv Arkiv II a fund managed by Gimv NV (ENXTBR:GIMB), SmartFin Capital I a fund managed by SmartFin Capital NV and Federal Holding and Investment Company on June 23, 2025. The investment marks a strong vote of confidence in Itineris’ strategy to become the global category leader in advanced software solutions for the utilities sector. Daiwa Corporate Advisory Limited acted as financial advisor for Itineris NV. Allen Overy Shearman Sterling LLP acted as legal advisor for Itineris NV. Four & Five acted as legal advisor for Itineris NV. Cobepa S.A. completed the acquisition of an unknown majority stake in Itineris NV from Participatiemaatschappij Vlaanderen NV, Gimv Arkiv II a fund managed by Gimv NV (ENXTBR:GIMB), SmartFin Capital I a fund managed by SmartFin Capital NV and Federal Holding and Investment Company on June 23, 2025.
공고 • May 28Bugaboo International B.V. acquired an unknown minority stake in Joolz from Gimv NV (ENXTBR:GIMB).Bugaboo International B.V. acquired an unknown minority stake in Joolz from Gimv NV (ENXTBR:GIMB) on May 27, 2025. Both Joolz and Bugaboo have agreed to join forces to accelerate their international growth in the fragmented worldwide stroller market. Bugaboo International B.V. completed the acquisition of an unknown minority stake in Joolz from Gimv NV (ENXTBR:GIMB) on May 27, 2025.
공고 • Mar 31Gimv NV to Report Fiscal Year 2025 Results on May 22, 2025Gimv NV announced that they will report fiscal year 2025 results on May 22, 2025
New Risk • Mar 13New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 28% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks Paying a dividend despite having no free cash flows. Shareholders have been diluted in the past year (28% increase in shares outstanding).
공고 • Feb 21Gimv NV agreed to acquired as unknown majority stake in The Spice Factory from Gilde Equity Management and Davy De Muyer.Gimv NV agreed to acquired as unknown majority stake in The Spice Factory from Gilde Equity Management and Davy De Muyer on February 20, 2025. Jorgen De Pelsmaeker, Chief Executive Officer, and the management team will reinvest alongside Gimv as the company embarks on its next phase of growth. Supported by the Gimv, The Spice Factory is expected to strengthen its market position and broaden its international reach. The transaction is expected to close before the end of March 2025.
공고 • Feb 04Gimv NV (ENXTBR:GIMB) acquired an unknown minority stake in Robojob NV.Gimv NV (ENXTBR:GIMB) acquired an unknown minority stake in Robojob NV on February 3, 2025. The aim of Gimv’s investment is to support RoboJob's international growth and enable the company to realise the full potential of the promising product offering. With this strong foundation complemented with the partnership that Gimv and the De Roovere family are now entering into, RoboJob is now in optimal shape to realise its growth ambitions. Gimv NV (ENXTBR:GIMB) completed the acquisition of an unknown minority stake in Robojob NV on February 3, 2025.
공고 • Dec 19B+N Referencia Zrt. agreed to acquire an unknown majority stake in Köberl Group from Gimv NV (ENXTBR:GIMB).B+N Referencia Zrt. agreed to acquire an unknown majority stake in Köberl Group from Gimv NV (ENXTBR:GIMB) on December 17, 2024. The deal is expected to close in the first quarter of 2025. Torsten Denker, Philipp Noack, Constantin vom Bauer, Olja Schmitt and Dominik Detels of IMAP Belgium acted as financial advisors for Gimv NV.
공고 • Dec 06Gimv NV, Eric Merilhou, Yann Dauce and the management of Tibbloc acquired an unknown majority stake in Tibbloc from Ciclad, SAS.Gimv NV, Eric Merilhou, Yann Dauce and the management of Tibbloc acquired an unknown majority stake in Tibbloc from Ciclad, SAS on December 4, 2024. A cash consideration will be paid by Gimv NV and the management. As part of consideration, an undisclosed value is paid towards common equity of Tibbloc. For the period ending December 31, 2023, Tibbloc reported total revenue of €40 million. Gimv NV, Eric Merilhou, Yann Dauce and the management of Tibbloc completed the acqusition of an unknown majority stake in Tibbloc from Ciclad, SAS on December 4, 2024.
공고 • Dec 04Gimv NV (ENXTBR:GIMB) and Wolf D. Koch agreed to acquire an unknown majority stake in Lupine Lighting Systems GmbH from Wolf D. Koch.Gimv NV (ENXTBR:GIMB) and Wolf D. Koch agreed to acquire an unknown majority stake in Lupine Lighting Systems GmbH from Wolf D. Koch on December 2, 2024. Wolf D. Koch, founder and chief executive officer, reinvesting part of his proceeds to hold a minority stake in the company. Financial details of the transaction remain undisclosed, pending successful closure.
공고 • Nov 22Fremman Limited agreed to acquire an unknown majority stake in rehaneo GmbH from Gimv NV (ENXTBR:GIMB).Fremman Limited agreed to acquire an unknown majority stake in rehaneo GmbH from Gimv NV (ENXTBR:GIMB) on November 20, 2024. The financing will be provided by Ares. Founder and chief executive officer Bruno Crone and co-founder and Chief operating officer Christoph Dühr remain significantly invested in the company and continue their management roles. The transaction is subject to approval by the German antitrust authorities and is expected to close in Q1 2025. Isabell Hitzer and Dr. Bernd Egbers of Astera Legal acted as legal advisor for Fremman Limited. Latham & Watkins acted as legal advisor to Ares.
공고 • Oct 16The Martens Brewery of Bocholt acquired United Dutch Breweries B.V. from Gimv NV (ENXTBR:GIMB) and management.The Martens Brewery of Bocholt acquired United Dutch Breweries B.V. from Gimv NV (ENXTBR:GIMB) and management on October 16, 2024. The Martens Brewery of Bocholt completed the acquisition of United Dutch Breweries B.V. from Gimv NV (ENXTBR:GIMB) and management on October 16, 2024.
공고 • Sep 06BiZZdesign BV agreed to acquire MEGA International S.A. from Gimv NV (ENXTBR:GIMB).BiZZdesign BV agreed to acquire MEGA International S.A. from Gimv NV (ENXTBR:GIMB) on September 4, 2024. The transaction is subject to approval by regulatory board / committee.
Upcoming Dividend • Jun 24Upcoming dividend of €1.82 per shareEligible shareholders must have bought the stock before 01 July 2024. Payment date: 26 July 2024. Payout ratio is a comfortable 33% but the company is not cash flow positive. Trailing yield: 5.7%. Within top quartile of German dividend payers (4.7%). Higher than average of industry peers (2.8%).
New Risk • Jun 10New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Paying a dividend despite having no free cash flows. Shareholders have been diluted in the past year (2.4% increase in shares outstanding).
공고 • May 22WorxInvest NV completed the acquisition of 27.81% stake in Gimv NV (ENXTBR:GIMB) from Flemish Community.WorxInvest NV signed an agreement to acquire 27.81% stake in Gimv NV (ENXTBR:GIMB) from Flemish Community for approximately €370 million on November 30, 2023. The transaction is subject to customary regulatory approvals., Freshfields Bruckhaus Deringer LLP and Ernst & Young served as accountant to WorxInvest on the transaction. Rothschild & Co and Stibbe advised the Flemish Region on the transaction. Morgan Stanley acted as financial advisor to WorxInvest NV. Koen Vanhaerents, Guillaume Nataf, Frans Muller and Bram Hoorelbeke of Baker & Mckenzie acted as legal advisor to Gimv. As of April 15, 2024, The European Commission approved WorxInvest to buy Gimv.WorxInvest NV completed the acquisition of 27.81% stake in Gimv NV (ENXTBR:GIMB) from Flemish Community on May 21, 2024. All regulatory approvals obtained.
Board Change • May 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Mar 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
공고 • Feb 28Sagard SAS acquired Groupe Acceo from Gimv NV (ENXTBR:GIMB).Sagard SAS acquired Groupe Acceo from Gimv NV (ENXTBR:GIMB) on February 27, 2024. Moncey Avocats acted as legal advisor, Natixis Partners and UBS M & A Mid-Cap acted as financial advisor, KPMG Corporate Finance France, Indefi and Marsh & Mclennan Companies France acted as due diligence provider to Sagard SAS. Capitalmind Corporate Finance Advisory acted as financial advisor, Hogan Lovells (Paris) LLP acted as legal advisor, Oderis Consulting and EY-Parthenon acted as due diligence provider to Groupe Acceo shareholders. Sagard SAS completed the acquisition of Groupe Acceo from Gimv NV (ENXTBR:GIMB) on February 27, 2024.
Board Change • Feb 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
공고 • Feb 03+ 2 more updatesGimv NV to Report Fiscal Year 2024 Results on May 23, 2024Gimv NV announced that they will report fiscal year 2024 results on May 23, 2024
Reported Earnings • Nov 25First half 2024 earnings released: EPS: €5.81 (vs €2.80 loss in 1H 2023)First half 2024 results: EPS: €5.81 (up from €2.80 loss in 1H 2023). Revenue: €203.5m (up 86% from 1H 2023). Net income: €158.2m (up €233.2m from 1H 2023). Profit margin: 78% (up from net loss in 1H 2023). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
Board Change • Nov 24Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Oct 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
공고 • Sep 19Crédit Mutuel Equity signed an agreement to acquire unknown majority stake in Groupe CLAIRE SAS from Gimv NV (ENXTBR:GIMB).Crédit Mutuel Equity signed an agreement to acquire unknown majority stake in Groupe CLAIRE SAS from Gimv NV (ENXTBR:GIMB) on September 18, 2023. Completion of the transaction remains subject to the recommendation of Groupe Claire's employee representative bodies, as well as the authorization of the French Competition Authority.
Board Change • Apr 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Feb 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Jan 12First half 2023 earnings released: €2.80 loss per share (vs €5.22 profit in 1H 2022)First half 2023 results: €2.80 loss per share (down from €5.22 profit in 1H 2022). Revenue: €109.3m (down 48% from 1H 2022). Net loss: €75.1m (down 155% from profit in 1H 2022). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
Board Change • Jan 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Nov 17Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
공고 • Oct 26Gimv NV to Report Fiscal Year 2023 Results on May 17, 2023Gimv NV announced that they will report fiscal year 2023 results on May 17, 2023
공고 • Oct 19Gimv NV, Annual General Meeting, Jun 28, 2023Gimv NV, Annual General Meeting, Jun 28, 2023.
Board Change • Sep 12Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Jul 25Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Jan 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Dec 17Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Nov 21First half 2022 earnings released: EPS €5.22 (vs €3.61 in 1H 2021)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2022 results: Revenue: €208.5m (up 21% from 1H 2021). Net income: €137.0m (up 46% from 1H 2021). Profit margin: 66% (up from 55% in 1H 2021). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 12Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Sep 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Independent Director Frank Verhaegen was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • May 22Full year 2021 earnings released: EPS €7.96 (vs €5.96 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: €331.9m (up 125% from FY 2020). Net income: €205.7m (up €357.3m from FY 2020). Profit margin: 62% (up from net loss in FY 2020). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Mar 05New 90-day low: €48.40The company is down 1.0% from its price of €49.10 on 04 December 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Capital Markets industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Feb 03New 90-day high: €50.80The company is up 12% from its price of €45.50 on 04 November 2020. The German market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Capital Markets industry, which is up 14% over the same period.
Is New 90 Day High Low • Dec 28New 90-day high: €50.30The company is up 6.0% from its price of €47.40 on 29 September 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Capital Markets industry, which is also up 6.0% over the same period.
Reported Earnings • Nov 22First half 2021 earnings released: EPS €3.61The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €172.5m (up 12% from 1H 2020). Net income: €94.0m (up 83% from 1H 2020). Profit margin: 55% (up from 33% in 1H 2020). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 81% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Nov 19New 90-day high: €48.10The company is up 6.0% from its price of €45.50 on 20 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Capital Markets industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Oct 22New 90-day low: €45.00The company is down 4.0% from its price of €46.85 on 24 July 2020. The German market is down 3.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Capital Markets industry, which is down 10.0% over the same period.